From bench to beside: luteolin’s therapeutic promise in neurological disorders

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Luteolin (3′,4′,5,7-tetrahydroxyflavone) is a naturally occurring flavonoid found in diverse plant families, including Apiaceae, Brassicaceae and Lamiaceae, and is a major bioactive component of Chinese medicines such as Chrysanthemum morifolium and Perilla frutescens. It possesses antidepressant, anti-inflammatory, antioxidant and neuroprotective activities, and has shown therapeutic potential in depression, Alzheimer’s disease (AD) and Parkinson’s disease (PD). Based on a comprehensive PubMed search, this review examines the shared pathological features-neuroinflammation, oxidative stress and synaptic dysfunction-across these three disorders and elucidates the pharmacological actions of luteolin. Clinical trial data were retrieved from NIH and ICTRP registries. We critically analyze current research limitations, including the lack of validated direct targets beyond PPARγ, the predominance of pathway-based evidence without orthogonal validation, and significant pharmacokinetic defects (low oral bioavailability, rapid glucuronidation, poor BBB penetration). While luteolin holds promise for central nervous system (CNS) disorders, its clinical translation requires advanced drug delivery systems (e.g., nano-formulations, brain-region-specific prodrugs), combination therapies or structural modification, and future cohort studies for prophylactic use. Addressing these priorities will be essential for its therapeutic development.

Keywords

Luteolin / Depression / Alzheimer’s disease / Parkinson’s disease / Neuroinflammation / Oxidative stress

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020; 19(3):255-265. https://doi.org/10.1016/s1474-4422(19)30411-9.

[2] Santomauro DF, Herrera AMM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312):1700-1712. https://doi.org/10.1016/S0140-6736(21)02143-7.

[3] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021; 397(10284):1577-1590. https://doi.org/10.1016/s0140-6736(20)32205-4.

[4] Armstrong MJ, Okun MS . Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020; 323(6):548-560. https://doi.org/10.1001/jama.2019.22360.

[5] Wolfe N, Katz DI, Albert ML, et al. Neuropsychological profile linked to low dopamine: in Alzheimer’s disease, major depression, and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990; 53(10):915-917. https://doi.org/10.1136/jnnp.53.10.915.

[6] Tirozzi A, Quiccione MS, Cerletti C, et al. A multi-trait association analysis of brain disorders and platelet traits identifies novel susceptibility loci for major depression, Alzheimer’s and Parkinson’s Disease. Cells. 2023; 12(2):245. https://doi.org/10.3390/cells12020245.

[7] Gendrisch F, Esser PR, Schempp CM, et al. Luteolin as a modulator of skin aging and inflammation. BioFactors. 2021; 47(2):170-180. https://doi.org/10.1002/biof.1699.

[8] Taheri Y, Sharifi-Rad J, Antika G, et al. Paving luteolin therapeutic potentialities and agro-food-pharma applications: emphasis on in vivo pharmacological effects and bioavailability traits. Oxid Med Cell Longev. 2021; 2021:1987588. https://doi.org/10.1155/2021/1987588.

[9] Daily JW, Kang S, Park S . Protection against Alzheimer’s disease by luteolin: role of brain glucose regulation, anti-inflammatory activity, and the gut microbiota-liver-brain axis. BioFactors. 2021; 47(2):218-231. https://doi.org/10.1002/biof.1703.

[10] Miean KH, Mohamed S . Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem. 2001; 49(6):3106-3112. https://doi.org/10.1021/jf000892m.

[11] Chagas M, Behrens MD, Moragas-Tellis CJ, et al. Flavonols and flavones as potential anti-inflammatory, antioxidant, and antibacterial compounds. Oxid Med Cell Longev. 2022; 2022:9966750. https://doi.org/10.1155/2022/9966750.

[12] Chen S, Liu J, Dong GQ, et al. Flavonoids and caffeoylquinic acids in Chrysanthemum morifolium Ramat flowers: a potentially rich source of bioactive compounds. Food Chem. 2021; 344:128733. https://doi.org/10.1016/j.foodchem.2020.128733.

[13] Nayak S, Boopathi S, Priya PS, et al. Luteolin, a promising quorum quencher mitigates virulence factors production in Pseudomonas aeruginosa - in vitro and in vivo approach. Microb Pathog. 2023; 180:106123. https://doi.org/10.1016/j.micpath.2023.106123.

[14] Sudhakaran G, Kesavan D, Ranjan Nayak SPR, et al. Bisphenol A-induced ovarian damage countered by luteolin: experiments in in vitro CHO cells and in vivo PCOS phenotype zebrafish. Tissue Cell. 2024; 91:102532. https://doi.org/10.1016/j.tice.2024.102532.

[15] Yuan NJ, Gong L, Tang KR, et al. An integrated pharmacology-based analysis for antidepressant mechanism of Chinese herbal formula Xiao-Yao-San. Front Pharmacol. 2020; 11:284. https://doi.org/10.3389/fphar.2020.00284.

[16] Yuan NJ, Zhu WJ, Ma QY, et al. Luteolin ameliorates chronic stress-induced depressive-like behaviors in mice by promoting the Arginase-1⁺ microglial phenotype via a PPARγ-dependent mechanism. Acta Pharmacol Sin. 2025; 46(3):575-591. https://doi.org/10.1038/s41401-024-01402-9.

[17] Nabavi SF, Braidy N, Gortzi O, et al. Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. Brain Res Bull. 2015; 119(Pt A):1-11. https://doi.org/10.1016/j.brainresbull.2015.09.002.

[18] Jayawickreme DK, Ekwosi C, Anand A, et al. Luteolin for neurodegenerative diseases: a review. Pharmacol Rep. 2024; 76(4):644-664. https://doi.org/10.1007/s43440-024-00610-8.

[19] Mahto K, Kuwar OK, Maloo A, et al. Therapeutic potential of luteolin in neurodegenerative disorders: targeting Nrf2, NF-κB, MAPK, and JAK-STAT pathways to combat neuroinflammation and apoptosis. Inflammopharmacology. 2025; 33(9):5011-5021. https://doi.org/10.1007/s10787-025-01846-3.

[20] Harerimana NV, Liu Y, Gerasimov ES, et al. Genetic evidence supporting a causal role of depression in Alzheimer's disease. Biol Psychiatry. 2022; 92(1):25-33. https://doi.org/10.1016/j.biopsych.2021.11.025.

[21] Zhao XY, Kong DW, Zhou QM, et al. Baicalein alleviates depression-like behavior in rotenone-induced Parkinson’s disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomed Pharmacother. 2021; 140:111556. https://doi.org/10.1016/j.biopha.2021.111556.

[22] van Heijst BF, Deserno MK, Rhebergen D, et al. Autism and depression are connected: a report of two complimentary network studies. Autism. 2020; 24(3):680-692. https://doi.org/10.1177/1362361319872373.

[23] Shen FM, Song ZJ, Xie P, et al. Polygonatum sibiricum polysaccharide prevents depression-like behaviors by reducing oxidative stress, inflammation, and cellular and synaptic damage. J Ethnopharmacol. 2021; 275:114164. https://doi.org/10.1016/j.jep.2021.114164.

[24] Hirsch EC, Hunot S . Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009; 8(4):382-97. https://doi.org/10.1016/s1474-4422(09)70062-6.

[25] Bouvier E, Brouillard F, Molet J, et al. Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression. Mol Psychiatry. 2017; 22(12):1701-1713. https://doi.org/10.1038/mp.2016.144.

[26] Davies DA, Adlimoghaddam A, Albensi BC . Role of Nrf2 in synaptic plasticity and memory in Alzheimer’s disease. Cells. 2021; 10(8):1884. https://doi.org/10.3390/cells10081884.

[27] Trist BG, Hare DJ, Double KL . Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell . 2019; 18(6):e13031. https://doi.org/10.1111/acel.13031.

[28] Fries GR, Saldana VA, Finnstein J, et al. Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatry. 2023; 28(1):284-297. https://doi.org/10.1038/s41380-022-01806-1.

[29] Peng L, Bestard-Lorigados I, Song W . The synapse as a treatment avenue for Alzheimer’s Disease. Mol Psychiatry. 2022; 27(7):2940-2949. https://doi.org/10.1038/s41380-022-01565-z.

[30] Nguyen M, Wong YC, Ysselstein D, et al. Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson’s disease. Trends Neurosci. 2019; 42(2):140-149. https://doi.org/10.1016/j.tins.2018.11.001.

[31] Sudhakaran G, Sreekutty AR, Subramaniyan S, et al. Skeletal and neurological risks demonstrated in zebrafish due to second-hand cigarette smoke and the neutralization of luteolin. Tissue Cell . 2023; 85:102259. https://doi.org/10.1016/j.tice.2023.102259.

[32] Sudhakaran G, Selvam M, Sreekutty AR, et al. Luteolin photo-protects zebrafish from environmental stressor ultraviolet radiation (UVB). J Toxicol Environ Health A. 2023; 86(19):720-734. https://doi.org/10.1080/15287394.2023.2249944.

[33] Infantino R, Schiano C, Luongo L, et al. MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microglia. Neurobiol Dis. 2022; 164:105611. https://doi.org/10.1016/j.nbd.2022.105611.

[34] Ryu D, Jee HJ, Kim SY, et al. Luteolin-7-O-glucuronide improves depression-like and stress coping behaviors in sleep deprivation stress model by activation of the BDNF signaling. Nutrients. 2022; 14(16):3314. https://doi.org/10.3390/nu14163314.

[35] Achour M, Ferdousi F, Sasaki K, et al. Luteolin modulates neural stem cells fate determination: in vitro study on human neural stem cells, and in vivo study on LPS-induced depression mice model. Front Cell Dev Biol. 2021; 9:753279. https://doi.org/10.3389/fcell.2021.753279.

[36] Wu XF, Xu HF, Zeng NX, et al. Luteolin alleviates depression-like behavior by modulating glycerophospholipid metabolism in the hippocampus and prefrontal cortex of LOD rats. CNS Neurosci Ther. 2024; 30(3):e14455. https://doi.org/10.1111/cns.14455.

[37] Cheng Y, Wang XX, Yu YH, et al. Noise induced depression-like behavior, neuroinflammation and synaptic plasticity impairments: the protective effects of luteolin. Neurochem Res. 2022; 47(11):3318-3330. https://doi.org/10.1007/s11064-022-03683-0.

[38] Mokhtari T, Lu M, El-Kenawy AE . Potential anxiolytic and antidepressant-like effects of luteolin in a chronic constriction injury rat model of neuropathic pain: role of oxidative stress, neurotrophins, and inflammatory factors. Int Immunopharmacol. 2023; 122:110520. https://doi.org/10.1016/j.intimp.2023.110520.

[39] Sur B, Lee B . Luteolin reduces fear, anxiety, and depression in rats with post-traumatic stress disorder. Anim Cells Syst (Seoul). 2022; 26(4):174-182. https://doi.org/10.1080/19768354.2022.2104925.

[40] Li HZ, Liu KG, Zeng NX, et al. Luteolin enhances choroid plexus 5-MTHF brain transport to promote hippocampal neurogenesis in LOD rats. Front Pharmacol. 2022; 13:826568. https://doi.org/10.3389/fphar.2022.826568.

[41] Akinrinde AS, Adebiyi OE . Neuroprotection by luteolin and gallic acid against cobalt chloride-induced behavioural, morphological and neurochemical alterations in Wistar rats. Neurotoxicology. 2019; 74:252-263. https://doi.org/10.1016/j.neuro.2019.07.005.

[42] Ishisaka M, Kakefuda K, Yamauchi M, et al. Luteolin shows an antidepressant-like effect via suppressing endoplasmic reticulum stress. Biol Pharm Bull. 2011; 34(9):1481-1486. https://doi.org/10.1248/bpb.34.1481.

[43] Tana, Nakagawa T. Luteolin ameliorates depression-like behaviors by suppressing ER stress in a mouse model of Alzheimer’s disease. Biochem Biophys Res Commun. 2022; 588:168-174. https://doi.org/10.1016/j.bbrc.2021.12.074.

[44] Gao AX, Xia TC, Peng ZT, et al. The ethanolic extract of peanut shell attenuates the depressive-like behaviors of mice through modulation of inflammation and gut microbiota. Food Res Int. 2023; 168:112765. https://doi.org/10.1016/j.foodres.2023.112765.

[45] Kaufmann FN, Menard C . Inflamed astrocytes: a path to depression led by menin. Neuron. 2018; 100(3):511-513. https://doi.org/10.1016/j.neuron.2018.10.033.

[46] Xie MX, Wang HQ, Gao TT, et al. The protective effect of luteolin on the depression-related dry eye disorder through Sirt1/NF-κB/NLRP3 pathway. Aging (Albany NY). 2023; 15(1):261-275. https://doi.org/10.18632/aging.204479.

[47] Kempuraj D, Thangavel R, Kempuraj DD, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. BioFactors. 2021; 47(2):190-197. https://doi.org/10.1002/biof.1687.

[48] Theoharides TC, Stewart JM, Hatziagelaki E, et al. Brain "fog", inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015; 9:225. https://doi.org/10.3389/fnins.2015.00225.

[49] Kou JJ, Shi JZ, He YY, et al. Luteolin alleviates cognitive impairment in Alzheimer’s disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation. Acta Pharmacol Sin. 2022; 43(4):840-849. https://doi.org/10.1038/s41401-021-00702-8.

[50] Ahmad S, Jo MH, Ikram M, et al. Deciphering the potential neuroprotective effects of luteolin against Aβ_1-42-induced Alzheimer’s disease. Int J Mol Sci. 2021; 22(17):9583. https://doi.org/10.3390/ijms22179583.

[51] Facchinetti R, Valenza M, Bronzuoli MR, et al. Looking for a treatment for the early stage of Alzheimer’s disease: preclinical evidence with co-ultramicronized palmitoylethanolamide and luteolin. Int J Mol Sci. 2020; 21(11):3802. https://doi.org/10.3390/ijms21113802.

[52] Abbas H, Sayed NSE, Youssef N, et al. Novel luteolin-loaded chitosan decorated nanoparticles for brain-targeting delivery in a sporadic Alzheimer’s disease mouse model: focus on antioxidant, anti-inflammatory, and amyloidogenic pathways. Pharmaceutics. 2022; 14(5):1003. https://doi.org/10.3390/pharmaceutics14051003.

[53] He ZJ, Li XQ, Wang Z, et al. Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ-dependent mechanism in Alzheimer’s disease. Redox Biol. 2023; 66:102848. https://doi.org/10.1016/j.redox.2023.102848.

[54] Park S, Kim DS, Kang S, et al. The combination of luteolin and l-theanine improved Alzheimer disease-like symptoms by potentiating hippocampal insulin signaling and decreasing neuroinflammation and norepinephrine degradation in amyloid-β-infused rats. Nutr Res. 2018; 60:116-131. https://doi.org/10.1016/j.nutres.2018.09.010.

[55] Tao X, Zhang R, Wang LG, et al. Luteolin and exercise combination therapy ameliorates amyloid-β_1-42 oligomers-induced cognitive impairment in AD mice by mediating neuroinflammation and autophagy. J Alzheimer’s Dis. 2023; 92(1):195-208. https://doi.org/10.3233/jad-220904.

[56] Wang H, Wang H, Cheng H, et al. Ameliorating effect of luteolin on memory impairment in an Alzheimer’s disease model. Mol Med Rep. 2016; 13(5):4215-4220. https://doi.org/10.3892/mmr.2016.5052.

[57] Sawmiller D, Li S, Shahaduzzaman M, et al. Luteolin reduces Alzheimer’s disease pathologies induced by traumatic brain injury. Int J Mol Sci. 2014; 15(1):895-904. https://doi.org/10.3390/ijms15010895.

[58] Zhang JX, Xing JG, Wang LL, et al. Luteolin inhibits fibrillary β-amyloid_1-40-induced inflammation in a human blood-brain barrier model by suppressing the p38 MAPK-mediated NF-κB signaling pathways. Molecules. 2017; 22(3):334. https://doi.org/10.3390/molecules22030334.

[59] Fu XB, Zhang JZ, Guo L, et al. Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav. 2014; 126:122-130. https://doi.org/10.1016/j.pbb.2014.09.005.

[60] Liu Y, Fu XB, Lan N, et al. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice. Behav Brain Res. 2014; 267:178-188. https://doi.org/10.1016/j.bbr.2014.02.040.

[61] van der Kant R, Goldstein LSB, Ossenkoppele R . Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21(1):21-35. https://doi.org/10.1038/s41583-019-0240-3.

[62] Guo TT, Zhang DH, Zeng YZ, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020; 15(1):40. https://doi.org/10.1186/s13024-020-00391-7.

[63] Naz F, Siddique YH . Role of genes and treatments for Parkinson’s disease. Open Biol J. 2020; 8(1):47-65. https://doi.org/10.2174/1874196702008010047.

[64] Feany MB, Bender WW . A drosophila model of Parkinson’s disease. Nature. 2000; 404(6776):394-398. https://doi.org/10.1038/35006074.

[65] Reudhabibadh R, Binlateh T, Chonpathompikunlert P, et al. Suppressing Cdk5 activity by luteolin inhibits MPP⁺-induced apoptotic of neuroblastoma through Erk/Drp1 and Fak/Akt/GSK3β pathways. Molecules. 2021; 26(5):1307. https://doi.org/10.3390/molecules26051307.

[66] Nishiguchi H, Omura T, Sato A, et al. Luteolin protects against 6-hydoroxydopamine-induced cell death via an upregulation of HRD1 and SEL1L. Neurochem Res. 2024; 49(1):117-128. https://doi.org/10.1007/s11064-023-04019-2.

[67] Siracusa R, Paterniti I, Impellizzeri D, et al. The association of plmitoylethanolamide with luteolin decreases neuroinflammation and stimulates autophagy in Parkinson’s disease model. CNS Neurol Disord Drug Targets. 2015; 14(10):1350-1365. https://doi.org/10.2174/1871527314666150821102823.

[68] Elmazoglu Z, Yar Saglam AS, Sonmez C, et al. Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson's disease and inflammatory pathways. Drug Chem Toxicol. 2020; 43(1):96-103. https://doi.org/10.1080/01480545.2018.1504961.

[69] Qin LY, Chen ZY, Yang L, et al. Luteolin-7-O-glucoside protects dopaminergic neurons by activating estrogen-receptor-mediated signaling pathway in MPTP-induced mice. Toxicology. 2019; 426:152256. https://doi.org/10.1016/j.tox.2019.152256.

[70] Guo DJ, Li F, Yu PH, et al. Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells. Pharm Biol. 2013; 51(2):190-196. https://doi.org/10.3109/13880209.2012.716852.

[71] Hu LW, Yen JH, Shen YT, et al. Luteolin modulates 6-hydroxydopamine-induced transcriptional changes of stress response pathways in PC12 cells. PLoS One. 2014; 9(5):e97880. https://doi.org/10.1371/journal.pone.0097880.

[72] Wu Y, Jiang XJ, Yang K, et al. Inhibition of α-synuclein contributes to the ameliorative effects of dietary flavonoids luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells. Toxicol Mech Methods. 2017; 27(8):598-608. https://doi.org/10.1080/15376516.2017.1339155.

[73] Chen HQ, Jin ZY, Wang XJ, et al. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett. 2008; 448(2):175-179. https://doi.org/10.1016/j.neulet.2008.10.046.

[74] Sanders LH, Greenamyre JT.Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med. 2013; 62:111-120. https://doi.org/10.1016/j.freeradbiomed.2013.01.005.

[75] Su X, Maguire-Zeiss KA, Giuliano R, et al. Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging. 2008; 29(11):1690-1701. https://doi.org/10.1016/j.neurobiolaging.2007.04.014.

[76] Zhang W, Wang TG, Pei Z, et al. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005; 19(6):533-542. https://doi.org/10.1096/fj.04-2758com.

[77] Hoenen C, Gustin A, Birck C, et al. Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS One. 2016; 11(9):e0162717. https://doi.org/10.1371/journal.pone.0162717.

[78] Dirscherl K, Karlstetter M, Ebert S, et al. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation. 2010; 7:3. https://doi.org/10.1186/1742-2094-7-3.

[79] Zenkov N, Menshchikova E, Tkachev V . Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc). 2013; 78:19-36. https://doi.org/10.1134/S0006297913010033.

[80] Cheng IF, Breen K . On the ability of four flavonoids, baicilein, luteolin, naringenin, and quercetin, to suppress the Fenton reaction of the iron-ATP complex. Biometals. 2000; 13(1):77-83. https://doi.org/10.1023/A:1009221829254.

[81] Puhl AC, Bernardes A, Silveira RL, et al. Mode of peroxisome proliferator-activated receptor γ activation by luteolin. Mol Pharmacol. 2012; 81(6):788-799. https://doi.org/10.1124/mol.111.076216.

[82] Zhu YM, Bao GS, Zhu GL, et al. Discovery and characterization of natural product luteolin as an effective inhibitor of human pyridoxal kinase. Bioorg Chem. 2024; 143:107057. https://doi.org/10.1016/j.bioorg.2023.107057.

[83] Lolli G, Cozza G, Mazzorana M, et al. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry. 2012; 51(31):6097-6107. https://doi.org/10.1021/bi300531c.

[84] Cao QC, Ding SQ, Zheng XE, et al. Luteolin induces GPX4-dependent ferroptosis and enhances immune activation in colon cancer. Phytomedicine. 2025; 146:157117. https://doi.org/10.1016/j.phymed.2025.157117.

[85] Xiang M, Lin XD, Chen HY . Luteolin inhibits ferroptosis of HUVEC by regulating the Sirt1/Nrf2 pathway. Cell Biochem Biophys. 2025; 83(4):5127-5140. https://doi.org/10.1007/s12013-025-01831-1.

[86] Johnson JL, Rupasinghe SG, Stefani F, et al. Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3β enzymatic activity by lowering the interaction energy within the binding cavity. J Med Food. 2011; 14(4):325-333. https://doi.org/10.1089/jmf.2010.0310.

[87] Zareei S, Pourmand S, Eskandarzadeh M, et al. In silico anti-alzheimer study of phytochemicals from Lamiaceae family through GSK3-β inhibition. Sci Rep. 2024; 14(1):834. https://doi.org/10.1038/s41598-023-47069-w.

[88] Hayakawa R, Ishii T, Fushimi T, et al. Luteolin protects human ARPE-19 retinal pigment epithelium cells from blue light-induced phototoxicity through activation of Nrf2/Keap1 signaling. Free Radic Res. 2025; 59(4):356-368. https://doi.org/10.1080/10715762.2025.2503832.

[89] Tian H, Zhang Y, Xiao SY, et al. Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizone-induced multiple sclerosis. Nutr Neurosci. 2025; 29(6):1-17. https://doi.org/10.1080/1028415x.2025.2599459.

[90] Smirnova NA, Kaidery NA, Hushpulian DM, et al. Bioactive flavonoids and catechols as Hif1 and Nrf2 protein stabilizers - Implications for Parkinson’s disease. Aging Dis. 2016; 7(6):745-762. https://doi.org/10.14336/ad.2016.0505.

[91] Wruck CJ, Claussen M, Fuhrmann G, et al. Luteolin protects rat PC12 and C6 cells against MPP⁺ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm Suppl. 2007;(72):57-67. https://doi.org/10.1007/978-3-211-73574-9_9.

[92] Wen L, Zhang WY, Hu J, et al. Luteolin target HSPB1 regulates endothelial cell ferroptosis to protect against radiation vascular injury. PLoS One. 2024; 19(10):e0311922. https://doi.org/10.1371/journal.pone.0311922.

[93] Kim JS, Jobin C . The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology. 2005; 115(3):375-387. https://doi.org/10.1111/j.1365-2567.2005.02156.x.

[94] Zhu JX, Yang HY, Hu WQ, et al. Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice. Inflammopharmacology. 2021; 29(4):1187-1200. https://doi.org/10.1007/s10787-021-00844-5.

[95] Zhang MJ, Yu JY, Liu A, et al. Luteolin in the Qi Bi Anshen decoction improves propionic acid-induced autism-like behavior in rats by inhibiting LRP1/MMP9. Phytomedicine. 2023; 118:154965. https://doi.org/10.1016/j.phymed.2023.154965.

[96] Oliveira AM, Cardoso SM, Ribeiro M, et al. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington’s disease mouse striatal cells. Neurochem Int. 2015; 91:1-12. https://doi.org/10.1016/j.neuint.2015.10.004.

[97] Smith C, Malek N, Grosset K, et al. Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies. J Neurol Neurosurg Psychiatry. 2019; 90(11):1234-1243. https://doi.org/10.1136/jnnp-2019-321111.

[98] Cisbani G, Maxan A, Kordower JH, et al. Presence of tau pathology within foetal neural allografts in patients with Huntington’s and Parkinson’s disease. Brain. 2017; 140(11):2982-2992. https://doi.org/10.1093/brain/awx255.

[99] Parnetti L, Farotti L, Eusebi P, et al. Differential role of CSF α-synuclein species, tau, and Aβ42 in Parkinson’s disease. Front Aging Neurosci. 2014; 6:53. https://doi.org/10.3389/fnagi.2014.00053.

[100] Zhang X, Gao F, Wang DD, et al. Tau pathology in Parkinson’s disease. Front Neurol. 2018; 9:809. https://doi.org/10.3389/fneur.2018.00809.

[101] Pan LN, Li CR, Meng LX, et al. Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease. Brain. 2022; 145(10):3454-3471. https://doi.org/10.1093/brain/awac171.

[102] Di Capua A, Adami R, Reverchon E . Production of luteolin/biopolymer microspheres by supercritical assisted atomization. Ind Eng Chem Res. 2017; 56(15):4334-4340. https://doi.org/10.1021/acs.iecr.7b00211.

[103] Peng B, Yan WD . Solubility of luteolin in ethanol + water mixed solvents at different temperatures. J Chem Eng Data. 2010; 55(1):583-585. https://doi.org/10.1021/je900381r.

[104] Wang ZY, Zeng MM, Wang ZJ, et al. Dietary luteolin: a narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism. J Agric Food Chem. 2021; 69(5):1441-1454. https://doi.org/10.1021/acs.jafc.0c08085.

[105] Jiang H, Pang XE . Luteolin as a dietary flavonoid for brain health: modulating neuroinflammation and cognitive decline in neurodegenerative disorders. Front Nutr. 2026; 13:1774416. https://doi.org/10.3389/fnut.2026.1774416.

[106] Andrade PB, Grosso C, Valentao P, et al. Flavonoids in neurodegeneration: limitations and strategies to cross CNS barriers. Curr Med Chem. 2016; 23(36):4151-4174. https://doi.org/10.2174/0929867323666160809094934.

[107] Zhu PY, Chen LY, Zhao YL, et al. A novel host-guest complex based on biotin functionalized polyamine-β-cyclodextrin for tumor targeted delivery of luteolin. J Mol Struct. 2021; 1237:130339. https://doi.org/10.1016/j.molstruc.2021.130339.

[108] Guru A, Murugan R, Almutairi BO, et al. Brain targeted luteolin-graphene oxide nanoparticle abrogates polyethylene terephthalate induced altered neurological response in zebrafish. Mol Biol Rep. 2023; 51(1):27. https://doi.org/10.1007/s11033-023-08960-x.

[109] Ali F, Siddique YH . Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2019; 18(5):352-365. https://doi.org/10.2174/1871527318666190319141835.

[110] Kaci H, Bodnárová S, Fliszár-Nyúl E, et al. Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. Biomed Pharmacother. 2023; 157:114078. https://doi.org/10.1016/j.biopha.2022.114078.